X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (114) 114
Publication (15) 15
Conference Proceeding (3) 3
Paper (3) 3
Patent (2) 2
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pharmacology & pharmacy (25) 25
animals (15) 15
humans (14) 14
index medicus (13) 13
male (13) 13
physics - high energy physics - phenomenology (13) 13
high energy physics - phenomenology (12) 12
female (11) 11
high energy physics (11) 11
phenomenology (11) 11
experiment (10) 10
non-small cell lung cancer (8) 8
rats (8) 8
physics, multidisciplinary (7) 7
adult (6) 6
physics, particles & fields (6) 6
rats, wistar (6) 6
biochemistry & molecular biology (5) 5
physics (5) 5
biophysics (4) 4
cancer (4) 4
disease (4) 4
models (4) 4
muscles (4) 4
pair production (4) 4
peptides (4) 4
physiological aspects (4) 4
physiology (4) 4
prostate cancer (4) 4
proteins (4) 4
spectroscopy (4) 4
7 t (3) 3
analysis (3) 3
article (3) 3
biology (3) 3
body weight (3) 3
cell biology (3) 3
cells (3) 3
cp violation (3) 3
decay (3) 3
diabetes mellitus, experimental - metabolism (3) 3
e+e annihilation (3) 3
ee (3) 3
egfr (3) 3
electric-dipole moment (3) 3
expression (3) 3
in-vivo-untersuchung (3) 3
internal medicine (3) 3
kidney - enzymology (3) 3
leg - physiology (3) 3
liver (3) 3
long te (3) 3
magnetic resonance spectroscopy (3) 3
magnetic resonance spectroscopy - methods (3) 3
medicine & public health (3) 3
melanoma (3) 3
muscle contraction - physiology (3) 3
particle physics (3) 3
phosphor (3) 3
polarization (3) 3
radiology, nuclear medicine & medical imaging (3) 3
reproducibility (3) 3
reproducibility of results (3) 3
research (3) 3
research article (3) 3
slovakia (3) 3
spectrum analysis (3) 3
supersymmetric standard model (3) 3
supersymmetry (3) 3
therapy (3) 3
tin dioxide (3) 3
absolute quantification (2) 2
abt-414 (2) 2
adenosine triphosphate (2) 2
adenosine triphosphate - metabolism (2) 2
advanced glycation (2) 2
age (2) 2
aged (2) 2
aged, 80 and over (2) 2
algorithms (2) 2
alzheimer's disease (2) 2
analytical chemistry (2) 2
annihilation (2) 2
anti-hgfr (2) 2
antibody-drug conjugate (2) 2
antioxidants - administration & dosage (2) 2
biochemical research methods (2) 2
biology and life sciences (2) 2
biomarkers (2) 2
biomechanical phenomena (2) 2
biomechanics (2) 2
biomedicine (2) 2
biopsy (2) 2
bladder cancer (2) 2
bleeding episodes (2) 2
blood glucose (2) 2
brain - metabolism (2) 2
breast cancer (2) 2
breast-cancer (2) 2
carbolines - administration & dosage (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


DRUGS OF THE FUTURE, ISSN 0377-8282, 09/2019, Volume 44, Issue 9, pp. 699 - 704
Monalizumab (IPH-2201; Innate Pharma/AstraZeneca) is a first-in-class humanized anti-NKG2-A/NKG2-8 type II integral membrane protein (NKG2A, KLRC1) monoclonal... 
Checkpoint inhibitor | PHARMACOLOGY & PHARMACY | IPH-2201 | Monalizumab | NKG2A
Journal Article
Drugs of the Future, ISSN 0377-8282, 2018, Volume 43, Issue 10, pp. 731 - 743
Upadacitinib tartrate (ABT-494) is a potent and selective tyrosine-protein kinase JAK1 inhibitor being developed for the treatment of systemic autoimmune... 
Upadacitinib tartrate | JAK1 inhibitors | Autoimmune inflammatory diseases | ABT-494 | Rheumatoid arthritis | RHEUMATOID-ARTHRITIS | SELECTIVE JAK-1 INHIBITOR | PHARMACOKINETICS | INADEQUATE RESPONSE | PHASE IIB | PHARMACOLOGY & PHARMACY
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 03/2018, Volume 43, Issue 3, pp. 181 - 187
Sitravatinib (MG-516, MGCD-516) is a novel multitargeted tyrosine kinase inhibitor (TKI) that blocks a number of receptor tyrosine kinases (RTKs), including... 
Renal cell carcinoma | Oncolytic drugs | Non-small cell lung cancer | Sitravatinib | MGCD516 | PHARMACOLOGY & PHARMACY | Receptor tyrosine kinase inhibitors | Targeted cancer therapy
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 09/2017, Volume 42, Issue 9, pp. 555 - 563
Prexasertib (LY-2606368) is a second-generation checkpoint kinase (Chk) 1 and Chk2 inhibitor being developed as a novel cancer therapy. The drug candidate was... 
Checkpoint kinase 1 inhibitor | PHARMACOLOGY & PHARMACY | LY-2606368 | Prexasertib | Cancer
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 07/2017, Volume 42, Issue 7, pp. 389 - 394
MGN-1703 (lefitolimod) is a novel, synthetic, covalently closed DNA molecule that activates the innate immune system via Toll-like receptor 9 (TLR9). The... 
Lefitolimod | MGN-1703 | RECEPTOR 9 AGONIST | TLR9 | dSLIM | PHARMACOLOGY & PHARMACY | Toll-like receptor 9 | IMMUNOMODULATOR MGN1703
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 05/2017, Volume 42, Issue 5, pp. 275 - 280
Larotrectinib (LOXO-101) is a small-molecule ATP-competitive oral inhibitor of the tropomyosin-related kinase (Trk) family of receptor kinases, including... 
LOXO-101 | Larotrectinib | FUSION | Tropomyosin-related kinase (Trk) inhibitor | PHARMACOLOGY & PHARMACY | KINASE INHIBITOR LOXO-101 | CANCER
Journal Article
Drugs of the Future, ISSN 0377-8282, 12/2016, Volume 41, Issue 12, pp. 715 - 723
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 12/2016, Volume 41, Issue 12, pp. 715 - 723
Lorlatinib (PF-06463922; Pfizer) is a novel small-molecule ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-protein... 
ALK INHIBITORS | NEUROBLASTOMA | DRIVEN | PF-06463922 | ANAPLASTIC LYMPHOMA KINASE | Lorlatinib | MODELS | Non-small cell lung cancer | CRIZOTINIB | RESISTANCE | PHARMACOLOGY & PHARMACY | ROS ONCOGENE 1 | MUTATIONS
Journal Article
Drugs of the Future, ISSN 0377-8282, 2017, Volume 42, Issue 9, pp. 555 - 563
Journal Article
Drugs of the Future, ISSN 0377-8282, 2017, Volume 42, Issue 7, pp. 389 - 394
Journal Article
Drugs of the Future, ISSN 0377-8282, 07/2016, Volume 41, Issue 7, pp. 411 - 416
Polatuzumab vedotin (anti-CD79b-MMAE; Genentech) is an anti-CD79b antibody-drug conjugate (ADC) consisting of the microtubule-disrupting agent monomethyl... 
Anti-CD79b monoclonal antibody | Follicular lymphoma -non-hodgkin's lymphoma | Polatuzumab vedotin | Tubulin polymerization inhibitors | NON-HODGKIN-LYMPHOMA | PHARMACOLOGY & PHARMACY | Follicular lymphoma Non-Hodgkin's lymphoma
Journal Article
Drugs of the Future, ISSN 0377-8282, 09/2016, Volume 41, Issue 9, pp. 535 - 538
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 09/2016, Volume 41, Issue 9, pp. 535 - 538
Emibetuzumab (LY-2875358, LA-480; Lilly) is a humanized bivalent monoclonal antibody, currently in phase II clinical trials for the treatment of advanced... 
LY-2875358 | Monoclonal antibody (MAb) | Non-small cell lung cancer (NSCLC) | PHARMACOLOGY & PHARMACY | Anti-HGFR | Emibetuzumab | LA-480
Journal Article
Drugs of the Future, ISSN 0377-8282, 04/2016, Volume 41, Issue 4, pp. 217 - 220
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 04/2016, Volume 41, Issue 4, pp. 217 - 220
Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC) comprised of the anti-epidermal growth factor receptor (EGFR) antibody ABT-806,... 
Depatuxizumab mafodotin | THERAPY | ABT-414 | PHARMACOLOGY & PHARMACY | Glioblastoma multiforme | EGFR | Antibody-drug conjugate
Journal Article
Drugs of the Future, ISSN 0377-8282, 06/2016, Volume 41, Issue 6, pp. 353 - 359
Tesevatinib is a novel second-generation inhibitor of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR-2),... 
VEGFR | HER2 | Tesevatinib | EGFR | Non-small cell lung cancer | GROWTH-FACTOR RECEPTOR | MUTANT | PHASE-II | PHARMACOLOGY & PHARMACY | EXEL-7647 | XL647
Journal Article
Drugs of the Future, ISSN 0377-8282, 02/2016, Volume 41, Issue 2, pp. 111 - 121
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 02/2016, Volume 41, Issue 2, pp. 111 - 121
Pemafibrate (K-877) is a highly potent, specific peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, with selective PPARa modulator (SPPARM... 
K-877 | (S)-2-HYDROXYBUTYROLACTONE | MANAGEMENT | Dyslipidemia | PPAR alpha | SPPARM alpha | AGONIST (R)-K-13675 | DENSITY-LIPOPROTEIN CHOLESTEROL | PLASMA | DISEASE | DRUGS | PHARMACOLOGY & PHARMACY | Pemafibrate
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.